• Explore /
  • Poster
  • / Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin.

Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin.

Abstract Poster

Authors

null

Chase Allain Shipp

University of California, San Francisco, San Francisco, CA

Chase Allain Shipp , Tanya Jindal , Kevin R Reyes , Xiaolin Zhu , Chien-Kuang Cornelia Ding , Emily Chan , Bradley A. Stohr , Prianka Deshmukh , Kelly N. Fitzgerald , Daniel Kwon , Rohit Bose , Arpita Desai , Ivan de Kouchkovsky , Rahul Raj Aggarwal , Eric J. Small , Lawrence Fong , Sima P. Porten , Terence W. Friedlander , Jonathan Chou , Vadim S Koshkin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 599)

DOI

10.1200/JCO.2024.42.4_suppl.599

Abstract #

599

Poster Bd #

G5

Abstract Disclosures

Similar Posters

First Author: Haojie Li

First Author: Vadim S Koshkin

First Author: Nicholas Mai

First Author: Evangelia Vlachou